Meet Richard
Richard has spent over 20 years in drug discovery, first as a computational chemist, and then in business development at the intersection of biology and technology. After his degree and Ph.D. in Biochemistry & Molecular Biophysics at the University of Oxford, he spent several years working in academia, biotech and government labs in California as a computational chemist. In 2008 he was hired as the Global Head of Computational Chemistry at Evotec, and after leading a team and several drug discovery projects, in 2013 became SVP Business Development, managing a team to build successful alliances between Evotec and biotech and pharma. One of many deals Richard helped form while at Evotec was Evotec’s series A investment in a small Dundee University spinout called Exscientia back in 2017, and he joined the company as Chief Business officer in late 2020 to enable partnerships such as those with BMS, Sanofi, Merck Darmstadt, EQRX, and the Gates Foundation, the acquisition of Allcyte, the company’s Nasdaq IPO in 2021, and finally the merger with Recursion in 2024.
At HAYA Therapeutics, Richard drives business strategy development by leveraging HAYA’s pioneering Regulatory Genome platform to create high-value biopharma partnerships, accelerate company growth, and secure life sciences funding.
